Protein Kinase Inhibitors: all 15,766 studies that test it
Page 16 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.
- Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung DiseaseRecruitingNCT06297096Phase 3
- Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAICRecruitingNCT06296563Phase 2
- Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment SurgeryRecruitingNCT06294847Phase 3
- CVL237 Tablets for APDS/PASLINot yet recruitingNCT06293716Phase 2/3
- Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene MutationRecruitingNCT06291987Phase 1
- A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 AlterationsNot yet recruitingNCT06287918Phase 1
- Drug Rediscovery for Rare Immune Mediated Inflammatory DiseasesRecruitingNCT06285539Phase 2
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerNot yet recruitingNCT06283303Phase 1
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal CancerNot yet recruitingNCT06283134Phase 1
- Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory TrialNot yet recruitingNCT06282536Phase 2
- Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.Enrolling by invitationNCT06281964Phase 3
- Expanding Liver Transplant Immunosuppression Minimization Via EverolimusRecruitingNCT06280950Phase 2
- Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract CancerRecruitingNCT06280508Phase 2
- A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With ApatinibRecruitingNCT06280105Phase 2
- Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin InhibitorsNot yet recruitingNCT06279494Phase 1/2
- Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell CarcinomaNot yet recruitingNCT06279403Phase 2
- Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical TrialRecruitingNCT06278870Phase 3
- Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKIRecruitingNCT06277674Phase 2
- DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)RecruitingNCT06276283Phase 2
- Regorafenib for Recurrent Meningioma (MIRAGE Trial)RecruitingNCT06275919Phase 2
- Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)RecruitingNCT06274801Phase 3
- Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)RecruitingNCT06266338Phase 2
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNCT06265545Not applicable
- Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant AmeloblastomaNot yet recruitingNCT06264778Phase 3
- Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT06263491Phase 2
- Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based TherapyRecruitingNCT06263153Phase 2
- CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML PatientsRecruitingNCT06262438Phase 2
- Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)RecruitingNCT06261125Phase 2
- Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet DisorderRecruitingNCT06261060Phase 2
- Study of APR-1051 in Patients With Advanced Solid TumorsRecruitingNCT06260514Phase 1
- NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast CancerRecruitingNCT06259929Phase 2
- Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLCRecruitingNCT06258642Not applicable
- Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in KoreaRecruitingNCT06257394Phase 2
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast CancerRecruitingNCT06255392Phase 3
- Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract CancerNot yet recruitingNCT06255262Phase 1/2
- A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCNot yet recruitingNCT06254599Phase 3
- A Phase 1/1b Study of IAM1363 in HER2 CancersRecruitingNCT06253871Phase 1
- Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT06253598Phase 2
- Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaRecruitingNCT06252675Phase 2
- An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDSRecruitingNCT06249997Phase 3
- A Phase IIII Study of AL8326 in Small Cell Lung CancerRecruitingNCT06247605Phase 3
- JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care UnitNot yet recruitingNCT06244862Phase 2
- Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid TumorsRecruitingNCT06243185Phase 2
- ERK Inhibitor JSI-1187 in Advanced Solid TumorsRecruitingNCT06239623Phase 1
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)RecruitingNCT06239272Phase 1/2
- Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.RecruitingNCT06236724Phase 2
- The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated VirusRecruitingNCT06236022Phase 4
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaRecruitingNCT06235801Phase 1/2
- A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast CancerRecruitingNCT06234137Not applicable
- Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label StudyRecruitingNCT06234007Phase 2
- A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT06233994Not applicable
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT06233461Phase 2
- Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHDRecruitingNCT06233110Phase 1
- Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06230471Phase 2
- A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's DiseaseRecruitingNCT06227910Phase 3
- Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes MellitusNot yet recruitingNCT06227221Phase 2
- Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell CarcinomasRecruitingNCT06225921Phase 1
- Gilteritinib for the Treatment of ALK NSCLCRecruitingNCT06225427Phase 1
- A Trial of Selinexor, Ruxolitinib and MethylprednisoloneRecruitingNCT06225310Phase 1
- Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic LeukemiaRecruitingNCT06224257Phase 2
- Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast CancerNot yet recruitingNCT06223698Phase 3
- Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJANot yet recruitingNCT06222944Phase 2
- SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 MutationRecruitingNCT06222580Phase 1
- Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological TumorsNot yet recruitingNCT06221774Phase 1/2
- Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung CancerNot yet recruitingNCT06221462Phase 2
- A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLRecruitingNCT06220487Phase 2
- A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver MetastasesNot yet recruitingNCT06218888Phase 2
- Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingNCT06218628Phase 1
- The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).RecruitingNCT06217185Phase 4
- Trilaciclib Combined With Chemotherapy for Perioperative Treatment of OsteosarcomaNot yet recruitingNCT06217003Phase 2
- Proteomic Guided First-line Precision Treatment of Renal Clear Cell CarcinomaRecruitingNCT06211790Phase 2
- A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic MalignancyNot yet recruitingNCT06211751Phase 1
- Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct CarcinomaRecruitingNCT06211114Phase 2
- HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)Not yet recruitingNCT06210334Phase 2
- Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent CancerRecruitingNCT06208657Phase 1/2
- Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence FactorsRecruitingNCT06208462Phase 2
- A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)RecruitingNCT06207123Phase 1/2
- Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant OsimertinibRecruitingNCT06206850Phase 2
- Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary SarcoidosisRecruitingNCT06205121Phase 2
- Drug Screening Using IMD in Bladder CancerEnrolling by invitationNCT06204614Early Phase 1
- Efficacy and Safety of Tofacitinib in Patients With Prurigo NodularisNot yet recruitingNCT06201715Not applicable
- A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal CancerRecruitingNCT06200363Phase 1
- Rivoceranib in Patients With Metastatic Thymic Epithelial TumorNot yet recruitingNCT06200233Phase 2
- PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of ImmunityRecruitingNCT06199427Phase 2
- Neoadjuvant Adebrelimab Plus Dalpiciclib in Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT06199271Phase 2
- Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/IIRecruitingNCT06195189Phase 1/2
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaRecruitingNCT06194929Phase 1/2
- A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal CancerRecruitingNCT06194734Phase 3
- To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyRecruitingNCT06192849Phase 2
- Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingNCT06192797Phase 2
- Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingNCT06192784Phase 2
- Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AMLRecruitingNCT06191263Phase 2
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerRecruitingNCT06190899Phase 1/2
- Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)RecruitingNCT06189209Phase 2
- Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1RecruitingNCT06188741Phase 2
- The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical StudyRecruitingNCT06188650Not applicable
- Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian CancerNot yet recruitingNCT06188455Phase 3
- HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular CarcinomaRecruitingNCT06187961Phase 2
- A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)Enrolling by invitationNCT06186804Phase 2
- Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialRecruitingNCT06184750Phase 2